<DOC>
	<DOCNO>NCT01783353</DOCNO>
	<brief_summary>Up one-third common wart remain recalcitrant , occurrence attribute impaired cell-mediated immunity . At present , guideline exist management recalcitrant cutaneous wart . Zinc , well-established immunomodulatory agent , show promise regard . Previous study document efficacy oral zinc use zinc sulfate give maximum dose 600 mg/day , equivalent 140 mg elemental zinc , three time recommend upper limit 40 mg elemental zinc per day . This raise concern safety tolerability . In Philippines , oral zinc widely available chelate form zinc gluconate , benefit improved absorption compare non-chelated compound zinc sulfate . This study seek determine zinc gluconate 300 mg/day , equivalent 40 mg elemental zinc , efficacious treat recalcitrant cutaneous wart . This lower dose may add benefit increase safety , tolerability , cost-effectiveness .</brief_summary>
	<brief_title>Oral Zinc Gluconate Treatment Recalcitrant Cutaneous Warts : A Randomized , Double-blind , Placebo-controlled Trial</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>1 . Male nonpregnant female 2 . Age 19 year old 3 . With â‰¥ one ( 1 ) recalcitrant common , mosaic , palmar , plantar , periungual wart/s 4 . Consent give 1 . Current history mental illness 2 . Current history malignancy 3 . Severe immunodeficiency state 4 . Pregnant lactate 5 . Documented adverse effect oral topical zinc exposure 6 . Oral intake zinc supplement past 12 month less 7 . Oral Intake H2 antagonists past 4 week less 8 . Oral intake immunosuppressive past 4 week less 9 . Concurrent usage treatment modality 10 . Current anogenital wart</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Recalcitrant cutaneous wart</keyword>
	<keyword>verruca</keyword>
</DOC>